Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Astrazeneca Aktiebolag

Tomoaki Nakamura

Yoshiaki Isobe

Yosuke Takanashi

Masanori Tobe

Katsumi Kubota

Toshihiko Sone

Tomoya Shiro

The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, Rrepresents a hydrogen atom, a Calkyl group, a Calkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; Rrepresents a hydrogen atom, a halogen atom, a cyano group, &#x2014;NRR, &#x2014;N&#x2550;CHN(CH), or an Calkyl group; Arand Arindependently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient. 

Uracil derivative and use thereof for medical purposes

A novel adenine compound represented by the formula (1): [wherein Ris substituted or unsubstituted alkyl, etc., X is oxygen, etc., Ais 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., Ais substituted or unsubstituted 6- to 10-membered aryl, etc., Land Lare independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.

Adenine compound

Growing community of inventors

Osaka, Japan

Tomoaki Nakamura